Waterloo Capital’s Quest Diagnostics DGX Stock Holding History

Waterloo Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.86M	Sell	24,819 -1,511	-6%	-$294K	0.34%	70
2025 Q4	$4.57M	Buy	26,330 +551	+2%	+$100K	0.33%	72
2025 Q3	$4.91M	Buy	25,779 +3,499	+16%	+$621K	0.37%	63
2025 Q2	$4M	Buy	22,280 +1,935	+10%	+$336K	0.32%	72
2025 Q1	$3.44M	Buy	20,345 +2,997	+17%	+$492K	0.32%	84
2024 Q4	$2.62M	Buy	17,348 +1,528	+10%	+$238K	0.28%	92
2024 Q3	$2.46M	Buy	15,820 +11,423	+260%	+$1.71M	0.27%	94
2024 Q2	$602K	Buy	4,397 +255	+6%	+$34.9K	0.07%	200
2024 Q1	$551K	Sell	4,142 -1,271	-23%	-$165K	0.07%	210
2023 Q4	$746K	Buy	+5,413	New	+$712K	0.12%	165

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Waterloo Capital's DGX Position: Q1 2026 in Review

Waterloo Capital reduced its Quest Diagnostics (DGX) stake by 5.7% in Q1 2026, selling an estimated $294K and leaving 24,819 shares worth $4.86M. The position accounts for 0.34% of the portfolio, ranked #70.

Waterloo Capital first reported a position in DGX in Q4 2023 and has held it in 10 quarters since. The position peaked at $4.91M in Q3 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Waterloo Capital held 24,819 shares of Quest Diagnostics worth $4.86M as of Q1 2026.
Waterloo Capital sold 1,511 Quest Diagnostics shares in Q1 2026, an estimated $294K.
Quest Diagnostics made up 0.34% of Waterloo Capital's portfolio in Q1 2026, its #70 holding.
Waterloo Capital first reported a position in Quest Diagnostics in Q4 2023 and has held it in 10 quarters since.
Waterloo Capital's Quest Diagnostics position peaked at $4.91M in Q3 2025.
1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Waterloo Capital's 13F filing for Q1 2026, filed 12 May 2026.